monitoring

CME Webcast Teaches on Preventive Cardiology

by

OSUWexnerbloglogo2014 CME Webcast Teaches on Preventive Cardiology. The best way to improve outcomes in cardiovascular disease is to not get it in the first place and today on MedNet21, we are going to show you what you can do to prevent heart disease in your patients. Let me welcome today’s guests. Dr. Wesley Milks is a cardiologist and Assistant Professor of Internal Medicine and Kelly Bartsch is a pharmacist specializing in lipid management.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: REVIEW
the mechanisms of action of the major medication classes utilized in the 2018 multi-society cholesterol guidelines; and UNDERSTAND the influence of the new cardiovascular outcomes trials for ezetimibe and the PCSK9 inhibitors on the new cholesterol guidelines; DEMONSTRATE understanding of key atherosclerotic risk and risk-enhancing factors as well as of recent pivotal lipid lowering treatment guidelines; and SELECT the appropriate target of lipid lowering therapy (e.g. LDL-C or non-HDL-C) with respect to the patient’s comorbid metabolic conditions.

You’ll also learn about the following:

  • Cholesterol level goals
  • Indications for medical treatment of lipids
  • Follow-up of patients started on cholesterol lowering drugs
  • Monitoring of cholesterol lowering drugs
  • CRP and other inflammatory markers

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Learn About New Therapies for Type 2 Diabetes

by

OSUWexnerbloglogo2014 Learn About New Therapies for Type 2 Diabetes. 25 years ago, the management of type II diabetes was easy. You started a patient on a sulfonylurea and then if their glucose level didn’t improve, you added in NPH insulin. But things have changed. And today, we have better and safer medications to treat diabetes. Which is a good thing because the prevalence of diabetes over the past 25 years has grown enormously and we really needed new treatments to fight against this public health threat. But with new treatments can come confusion about which to use in different clinical situations. Joining our moderator on this CME webcast, to update us on the management of type 2 diabetes is endocrinologist and Assistant Professor of Internal Medicine from the Ohio State University, Dr. Joshua Joseph.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DESCRIBE the role of new medical therapies in hypoglycemia; and DESCRIBE the role of new medical therapies in cardiovascular disease.

You’ll also learn about the following:

  • New directions in the treatment of type 2 diabetes
  • Hemoglobin A1C targets
  • Treatment of type 2 diabetes when medication cost is a consideration
  • New glucose monitoring technologies

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Learn About New Developments in Asthma on CME Webcast

by

OSUWexnerbloglogo2014 Learn About New Developments in Asthma on CME Webcast. Today on MedNet, we’re going to tell you about the newest developments in asthma management to help you choose the right medications for your patients. Joining our moderator in the studio to update us on asthma management in adults is pulmonologist and Associate Professor of Internal Medicine, Dr. Jennifer McCallister. And then to update us on asthma management in children is pulmonologist and Associate Professor of Pediatrics, Dr. Elizabeth Allen.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DISCUSS important safety considerations in the use of long-acting beta-agonists in asthma care; SELECT the most appropriate initial inhaler therapy for a patient with asthma-COPD overlap; IDENTIFY new treatment options for both acute and chronic asthma management; and RECOGNIZE protracted bacterial bronchitis – an asthma mimic in young children.

You’ll also learn about the following:

  • Pathogenesis of asthma
  • Diagnosing asthma in children
  • Equivalency of different brands of inhaled corticosteroids and long-acting beta agonists
  • Asthma medications and pregnancy
  • Allergy testing and desensitization
  • School-based asthma treatment program
  • Exhaled nitric oxide
  • Leukotriene inhibitors in adult asthma
  • Bronchial thermoplasty
  • Peak flow monitoring
  • Role of increasing the dose of inhaled steroids in asthma exacerbations

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

CME Webcast Teaches on Immunosuppressant Medications

by

OSUWexnerbloglogo2014 CME Webcast Teaches on Immunosuppressant Medications. More and more, primary care physicians and hospitalists are finding themselves taking care of patients who have been started on immunosuppressant medication a transplant physician, rheumatologist, nephrologist, or pulmonologist. On this CME webcast, we’re going to tell you what you need to know about these medications, their side effects, and their complications. Let me introduce our guests. Dr. Brian Keller is a lung transplant pulmonologist and Assistant Professor Internal Medicine at The Ohio State University. And Pamela Burcham is a lung transplant specialty pharmacist from the OSU Wexner Medical Center.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DISCUSS indications for immunosuppressive therapies; and DESCRIBE prophylaxis immunization, and pregnancy considerations for patients on Immunosuppressive therapy; UNDERSTAND the indications for individual immunosuppressants; and DESCRIBE the common adverse effects and monitoring parameters of the immunosuppressive medications.

You’ll also learn about the following:

  • Common indications for immunosuppressant medications
  • Commonly used immunosuppressant medications
  • Food safety for patients taking immunosuppressant medications
  • Pneumocystis jiroveci clinical presentation
  • Indications for TNF inhibitors
  • Infection risk of TNF inhibitors
  • Management of immunosuppressants in the perioperative period
  • Travel safety when taking an immunosuppressant
  • Bone health and corticosteroids
  • Eye health and corticosteroids
  • Monitoring for methotrexate-induced hepatotoxicity
  • Thiopurine methylytransferase
  • Cyclophosphamide

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Discover Device Therapies for Heart Failure on Webcast

by

OSUWexnerbloglogo2014 Discover Device Therapies for Heart Failure on Webcast. In the past, we could prescribe medications or do a heart transplant, but that was about it. Now we have new devices that can help our patients with heart failure. On this CME webcast, we’re going to hear about these new devices to show you how these treatments can help them live longer and better lives. Joining our moderator in the studio are cardiologists and heart failure experts from the Ohio State University. Dr. Rami Kahwash is an Associate Professor of Internal Medicine and he is the Director of the Cardiovascular Research Organization at OSU. And Dr. Sitaramesh Emani is an Assistant Professor of Internal Medicine and the Director of Heart Failure Clinical Trials.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DESCRIBE the primary prevention strategies of the prevention of sudden cardiac death in chronic systolic heart failure and the role of Cardiac Resynchronization therapy (CRT); and UNDERSTAND indications of the new defibrillation strategies (wearable ICD and subcutaneous ICD) in the prevention of sudden cardiac death.

You’ll also learn about the following:

  • Medications versus implantable cardiac defibrillators
  • Implantable cardiac monitoring devices
  • Precautions when caring for patients with a ventricular assist device
  • Complications of ventricular assist devices
  • Investigational devices
  • Current role of the intra-aortic balloon pump

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.